logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Celgene Quanticel Research, Inc.


USPTO Granted Patents = 108

% Expired Patents = 3.7


Forward Citations = 186

Loading Chart...
Loading Chart...

36 inventors (with patents filed for the assignee):

goldMedal Jeffrey Alan Stafford (76 out of 143 patents)

silverMedal James Marvin Veal (72 out of 104 patents)

bronzeMedal Toufike Kanouni (57 out of 86 patents)

4.  Young K Chen (55 out of 63 patents)

5.  Michael Brennan Wallace (52 out of 94 patents)

6.  Zhe Nie (31 out of 47 patents)

7.  Amogh Boloor (27 out of 33 patents)

8.  Stephen W Kaldor (18 out of 68 patents)

9.  Robert Cho (8 out of 9 patents)

10.  Juan Manuel Betancort (7 out of 19 patents)

11.  Aaron Nguyen (4 out of 10 patents)

12.  Michael John Bennett (4 out of 11 patents)

13.  Matthew Michael Kreilein (4 out of 18 patents)

14.  Jiangchun Xu (4 out of 55 patents)

15.  Paula Alessandra Tavares-Greco (4 out of 10 patents)


Core Competencies:
KDM4 Inhibitors
Azacitidine
Venetoclax
Gilteritinib
Midostaurin
Lysine Specific Demethylase-1
Bromodomain Inhibitors
Combination Therapy
Therapeutic Compounds
Solid Tumors
Non-Hodgkin's Lymphomas
Myelodysplastic Syndrome

108 patents:

1. 12729183 - Process for the preparation of bromodomain inhibitor (2026-09-08),
2. 12516024 - KDM4 INHIBITORS (2026-01-06),
3. 12447171 - Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome (2025-10-21),
4. 12172998 - Histone demethylase inhibitors (2024-12-24),
5. 11987560 - Inhibitors of lysine specific demethylase-1 (2024-05-21),
6. 11890275 - Therapeutic compounds (2024-02-06),
7. 11884680 - Bromodomain inhibitors (2024-01-30),
8. 11884648 - Histone demethylase inhibitors (2024-01-30),
9. 11679106 - Bromodomain inhibitor (2023-06-20),
10. 11639333 - Histone demethylase inhibitors (2023-05-02),
11. 11566004 - Process for the preparation of bromodomain inhibitor (2023-01-31),
12. 11535616 - Histone demethylase inhibitors (2022-12-27),
13. 11464771 - Bromodomain and extra-terminal protein inhibitor combination therapy (2022-10-11),
14. 11214542 - Histone demethylase inhibitors (2022-01-04),
15. 11084793 - Inhibitors of lysine specific demethylase-1 (2021-08-10),
Company Overview
Celgene Quanticel Research, Inc., based in San Diego, CA, specializes in the development of innovative therapies targeting histone demethylase inhibitors. The company focuses on advancing treatments that leverage KDM4 inhibitors and other key compounds such as azacitidine, venetoclax, gilteritinib, and midostaurin. Their research emphasizes combination therapies and the role of lysine-specific demethylase-1 and bromodomain inhibitors in cancer treatment, aiming to enhance therapeutic efficacy and patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

108 Patents

#59 in San Diego, CA

#804 in California

#3,538 in US

#7,281 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Celgene Quanticel Research, Inc.

Forward Citations = 186

36 inventors:

goldMedal Jeffrey Alan Stafford (76 out of 143 patents)

silverMedal James Marvin Veal (72 out of 104 patents)

bronzeMedal Toufike Kanouni (57 out of 86 patents)

4.  Young K Chen (55 out of 63 patents)

5.  Michael Brennan Wallace (52 out of 94 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Celgene Quanticel Research, Inc.. Retrieved from https://idiyas.com/company/celgene-quanticel-research

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…